Dopamine and G protein-coupled receptor kinase 4 in the kidney: Role in blood pressure regulation  by Jose, Pedro A. et al.
Biochimica et Biophysica Acta 1802 (2010) 1259–1267
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isReview
Dopamine and G protein-coupled receptor kinase 4 in the kidney: Role in blood
pressure regulation
Pedro A. Jose a,⁎, Patricio Soares-da-Silva b, Gilbert M. Eisner c, Robin A. Felder d
a Center for Molecular Physiology Research, Children's National Medical Center, George Washington University for the Health Sciences, Washington, DC, USA
b Institute of Pharmacology and Therapeutics Faculty of Medicine, University of Porto, Porto, Portugal
c Department of Medicine, Georgetown University Medical Center, Washington, DC, USA
d Department of Pathology, University of Virginia, Charlottesville, VA, USAAbbreviations: AT1R, angiotensin type 1 receptor; D1
D2 dopamine receptor, D3R, D3 dopamine receptor, D4R,
dopamine receptor; ENaC, epithelial sodium chann
receptor; GRK, G protein-coupled receptor kinase; GRK
kinase type 2; GRK3, G protein-coupled receptor kin
coupled receptor kinase type 4; GRK5, G protein-coupled
G protein-coupled receptor kinase type 6; GWAS, gen
Na/PiIIa, sodium phosphate cotransporter type IIa; NCC
ter; NHE1, sodium hydrogen exchanger type 1; NHE3
type 3; NKCC2, sodium potassium 2 chloride cotranspo
⁎ Corresponding author. Center for Molecular Ph
National Medical Center, 111 Michigan Avenue, NW,
Tel.: +1 202 476 5715; fax: +1 202 476 6285.
E-mail address: pjose@cnmc.org (P.A. Jose).
0925-4439/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbadis.2010.02.004a b s t r a c ta r t i c l e i n f oArticle history:
Received 31 October 2009
Received in revised form 5 February 2010
Accepted 7 February 2010
Available online 12 February 2010
Keywords:
Dopamine
Dopamine receptors
G protein-coupled receptor kinase 4
Sodium transport
Essential hypertensionComplex interactions between genes and environment result in a sodium-induced elevation in blood
pressure (salt sensitivity) and/or hypertension that lead to signiﬁcant morbidity and mortality affecting up
to 25% of the middle-aged adult population worldwide. Determining the etiology of genetic and/or
environmentally-induced high blood pressure has been difﬁcult because of the many interacting systems
involved. Two main pathways have been implicated as principal determinants of blood pressure since they
are located in the kidney (the key organ responsible for blood pressure regulation), and have profound
effects on sodium balance: the dopaminergic and renin–angiotensin systems. These systems counteract or
modulate each other, in concert with a host of intracellular second messenger pathways to regulate sodium
and water balance. In particular, the G protein-coupled receptor kinase type 4 (GRK4) appears to play a key
role in regulating dopaminergic-mediated natriuresis. Constitutively activated GRK4 gene variants (R65L,
A142V, and A486V), by themselves or by their interaction with other genes involved in blood pressure
regulation, are associated with essential hypertension and/or salt-sensitive hypertension in several ethnic
groups. GRK4γ 142V transgenic mice are hypertensive on normal salt intake while GRK4γ 486V transgenic
mice develop hypertension only with an increase in salt intake. GRK4 gene variants have been shown to
hyperphosphorylate, desensitize, and internalize two members of the dopamine receptor family, the D1
(D1R) and D3 (D3R) dopamine receptors, but also increase the expression of a key receptor of the renin–
angiotensin system, the angiotensin type 1 receptor (AT1R). Knowledge of the numerous blood pressure
regulatory pathways involving angiotensin and dopamine may provide new therapeutic approaches to the
pharmacological regulation of sodium excretion and ultimately blood pressure control.R, D1 dopamine receptor; D2R,
D4 dopamine receptor; D5R, D5
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Dopamine is important in the regulation of sodium balance and
blood pressure via renal mechanisms [1,2]. The afﬁnity of dopamine
for its receptors is in the nanomolar range; higher concentrations
occupy other GPCRs [1,2]. Circulating dopamine concentrations(picomolar range) are not sufﬁciently high to activate dopamine
receptors, but high nanomolar concentrations can be attained in
dopamine-producing tissues (e.g., renal proximal tubule, jejunum).
Independent of innervation, renal proximal tubules synthesize
dopamine that is not converted to norepinephrine [1,2]. Dietary
sodium and intracellular sodium are the major determinants for the
renal tubular synthesis/release of dopamine [3–9]; the stimulatory
effect of increased dietary sodium on renal dopamine production is
impaired in some hypertensive humans [10–12]. Locally generated
dopamine, which is secreted preferentially into the renal tubular
lumen, and acts in an autocrine/paracrine manner [1,2,13], is
responsible for over 50% of incremental sodium excretion, especially
when sodium intake is increased. The increase in renal sodium
excretion due to dopamine is caused by inhibition of sodium
transporter and pump activities, in the short-term, and a decrease
in the expression of several sodium transporters, in the long-term. The
inhibitory effect of dopamine on sodium pump activity is tissue/cell-
speciﬁc. Indeed, in alveolar epithelial cells, dopamine stimulates
rather than inhibits sodium channel and pump [14–16]. The short-
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at caveolin-1 rich plasma membrane microdomains followed by their
internalization, via scaffolding proteins [17–32]. The long-term
inhibition of sodium transport by dopamine may involve the
regulation of protein expression [33].
Dopamine can also affect sodium balance by regulating ﬂuid and
sodium intake via the “appetite” centers in the brain [34–36] and
gastrointestinal transport [37]. Dopamine regulates the secretion/
release of other hormones and humoral agents [38–44] that also
regulate sodium balance and blood pressure (1). These hormonesmay
interact with dopamine to increase (e.g., atrial natriuretic peptide
[45], prolactin [46]) or decrease its inhibitory effect on sodium
transport (e.g., angiotensin II [47–50], insulin [51,52]). Oxidative
stress and inﬂammation also impair dopamine receptor function [53–
58]. This article reviews the role of dopamine and dopamine receptor
subtypes and their regulation by G protein-coupled receptor kinase
(GRK4), with special emphasis on GRK4 type 4 (GRK4), in essential
hypertension.
2. Renal dopamine receptor subtypes
In mammals, dopamine exerts its actions via two receptor classes,
D1-like and D2-like, that belong to the α group of the rhodopsin-like
family of GPCRs[1,2,59]. The D1-like receptors, D1 (D1R) and D5 (D5R)
subtypes (also called D1AR and D1BR in rodents), stimulate adenylyl
cyclases [1,2,60]. The D1R, but not D5R, couples to GO [61]. In contrast,
D5R, but not D1R, couples to Gz and Gα12/13 [62,63]. The D1-like
receptors are also linked to Gαq [64–67]. The linkage of G protein
subunits to the speciﬁc D1-like receptor is tissue-speciﬁc. In
ﬁbroblasts, the D1R couples to Gαq and phospholipase C [68] . More
recently, the D5R has also been linked to stimulation of phospholipase
C activity of neural tissue (hippocampus, cortex, and striatum) [69]. In
neural (striatal) cells, D1R mediated-stimulation of phospholipase C
requires the presence of D2R, while D5R, by itself, increases calcium
mobilization that is inhibited by D2R [70]. However, in a rat pituitary
adenoma cell line, GH4C1, transfected with the D5R, the D5R actually
decreases inositol phosphate production [71]. Therefore, the linkage
between D1R and D5R to phospholipase C activation is cell-speciﬁc.
The D2-like receptors, D2R, D3R, and D4R, couple to G-proteins Gαi
and Go, inhibit adenylyl cyclase and calcium channel activities, and
modulate potassium channel activity [1,2,60]. There are two isoforms
of D2R; postsynaptic D2R effects are mediated by the long isoform,
D2LR, while presynaptic D2R effects are mediated by the short isoform,
D2SR [60]. There could be seven distinct alternatively spliced D3R
variants. The full-length D3R and a shorter receptor isoform, the D3SR,
bind to dopamine. There are ﬁve other alternatively spliced D3R
variants that do not bind dopamine, including D3Rnf, but regulate
receptor dimerization [72]. Different numbers of 16 amino acid
repeats in the third cytoplasmic loop cause several human D4R
isoforms (e.g., D4-2, D4-4, and D4-7) [73]. The role of these D4R
isoforms remains to be determined. However, the D4R long (at least
one 7 to 10 repeat) has been reported to be associated with higher
diastolic and systolic blood pressure [74].
The D3Rmay also couple to Gαq in renal proximal tubule cells [75].
The D1R and D2R heterodimer stimulates phospholipase C but the
D2SR can stimulate phospholipase D, independent of D1R [76]; the
latter enzyme is inhibited by D5R [57]. These effects need not negate
each other because, as mentioned earlier, the D2SR is presynaptic,
while the inhibition of phospholipase D by D5R occurs in renal
proximal tubule cells. The D4R may also regulate phospholipase C-
coupled D1-like receptor action, e.g., D1-like receptor-mediated
grooming [77].
All of the dopamine receptor subtypes are expressed in the renal
tubule and renal vasculature. However, dopamine receptors are not
distributed evenly along the mammalian nephron. All members of the
dopamine receptor family are present in the renal proximal tubule.The medullary thick ascending limb of Henle expresses D1R, D3R, and
D5R while the cortical thick ascending limb expresses D3R only. The
distal convoluted tubule expresses D1R and D3R, while the collecting
duct expresses all members of the dopamine receptor family except
D2R [1,78,79].
Dopamine inhibits sodium transport at multiple sites along the
renal tubule and acts on multiple targets (NHE1 [80], NHE3
[22,75,81,82], Na/PiIIa[24,31,83,84], Na+/HCO3− cotransporter [30],
Cl−/HCO3− exchanger [85], Na+/K+ ATPase [17–19,23,27,28,37,50,86–
91], and probably NCC [92]. Dopamine, via the D4R, may also inhibit
ENaC [93,94] and arginine vasopressin-dependent sodium transport
and water permeability [94]. Dopamine stimulates NKCC2 in
medullary thick ascending limb, but because Na+/K+ ATPase is
inhibited, overall transport is decreased [95]. There is tissue-speciﬁc
regulation of sodium transport by dopamine. For example, in
pulmonary alveolar cells, dopamine stimulates Na+/K+ ATPase [91],
and D2LR stimulates Na+/K+ ATPase in murine ﬁbroblasts [96]. D1R
and D2R, on the one hand, and Na+/K+ ATPase, on the other, can also
negatively regulate each other in HEK293T cells by direct protein–
protein interaction [97].While the inhibition of Na+/K+ ATPase in the
kidney by dopamine under conditions of NaCl excess is beneﬁcial,
inhibition of Na+/K+ ATPase activity in neuronal cells by high
concentrations of dopamine can lead to cell death [98]. Inhibition of
Na+/K+ ATPase activity in vascular smooth muscle cells would
increase vascular resistance, as has been reported in the rat tail [99].
Low concentrations of dopamine, however, decreases systemic
vascular resistance, probably by other mechanisms [100–102], e.g.,
opening of potassium channels [103] that is mediated by D5R but not
D1R, at least in human coronary arteries [104].
The autocrine/paracrine regulation of renal tubular sodium
transport, via D1-like receptors, is mediated by tubular and not by
hemodynamic mechanisms [105–108]. Thus, systemically adminis-
tered dopaminergic drugs may not mimic the autocrine/paracrine
function of dopamine. However, D3R may regulate glomerular
dynamics [109]. The quantitative contribution of a particular
dopamine receptor subtype to renal sodium transport and glomerular
dynamics has not been studied. However, the D1R is responsible for
≈80% of D1-like receptor activity in renal proximal tubules [110]
while the D5R may be more important in the distal nephron [92,111].
Each of the dopamine receptor subtypes, alone, or via interaction with
the other dopamine receptor subtypes or other GPCRs regulate
sodium transport in a unique fashion [1,2,78]. Indeed, disruption of
any of the dopamine receptor genes in mice results in hypertension,
the pathogenesis of which is speciﬁc for each subtype [1,78].
3. Regulation of dopamine receptor function
As with other GPCRs, dopamine receptor signal transduction is
regulated precisely [112–119]. Loss of receptor responsiveness
(desensitization) is a mechanism that dampens short-term agonist
effects following repeated agonist exposure. At least three families of
regulatory molecules contribute to GPCR desensitization: second
messenger-dependent protein kinases, GRKs, and arrestins [112–
119]. Desensitization of GPCRs involves phosphorylation, sequestra-
tion/internalization, and degradation of receptors.
Homologous desensitization, in response to agonist stimulation,
occurs via action of a member(s) of the GRK family [112–119].
Heterologous desensitization, mediated by second messenger-depen-
dent kinases, occurs when a decrease in receptor responsiveness is
induced by a ligand other than its own speciﬁc ligand. The
phosphorylation of GPCRs, including the D1R, leads to the binding of
amember(s) of the arrestin family, uncoupling of the receptor from its
G protein complex, and a decrease in its functional response. The
phosphorylated GPCR/β-arrestin complex undergoes endocytosis/
internalization via clathrin-coated pits into a series of endosomal
units, where the GPCR is dephosphorylated, and recycled back to the
Table 1
G protein-coupled receptor kinases involved in speciﬁc dopamine receptor signaling.
Dopamine receptor
subtype
G protein-coupled
receptor kinase
References
D1R (in differentiated
kidney cells)
GRK2, GRK4 (GRK4α and GRK4γ
in humans#, GRK4E in rats)
[53,112,121–123]
(in embryonic kidney cells) GRK2, GRK3, GRK4α but not
GRK4γ, GRK5*
[113,114]
(in intestines but not
kidney cells)
GRK6 [120,124]
D2R GRK2, GRK3, GRK5, GRK6 [73,148,149]
D3R (in kidney cells) GRK2, GRK3, GRK4γNGRK4α [129,151]
D4R GRK2 or GRK3? [73]
D5R ?
*GRK5 increased agonist-dependent phosphorylation of rat D1R one report [114], but
not in another report [113]. #GRK4α and GRK4γ desensitize the human D1R [112] while
GRK4α but not GRKγ desensitizes the rat D1R [113]. ?unknown or not deﬁnite.
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somes and/or lysosomes.
3.1. G protein-coupled receptor kinase (GRK)
There are seven GRKs in humans: GRKs 1 and 7 belong to the opsin
kinase family, GRKs 2 and 3 belong to the β-adrenergic receptor
kinase (βARK) family, and GRKs 4, 5, and 6 belong to the GRK4 family
[116]. The tissue distribution of GRK4 is different from the other GRKs
[117]. GRKs 1 and 7 are expressed in rods and cones, respectively.
GRKs 2, 3, 5, and 6 are ubiquitously expressed while GRK4 is
expressed to a greater extent in the testes and myometrium and to a
lesser extent in speciﬁc brain areas [119], intestines [120], and the
kidney [112,117].
3.2. GRK2 and GRK4 and renal D1R
The D1R (but not D5R), expressed endogenously in human
[19,112,121] and rat renal proximal tubule cells [52,122,123], is
regulated to a lesser extent by GRK2 and to a greater extent by GRK4
in human kidneys [121], but the converse may be true in rat kidneys
[53,123]. In a human embryonic kidney cell line (HEK293), over-
expression of GRK3 also desensitizes the ratD1R [114]; a role for GRK5 in
the desensitization of the rat D1R is not settled (113, 114). GRK6 is not
important in the regulation of D1R in the kidney [124] but it is important
in the desensitization of the D1R in intestinal crypt cells [120],
emphasizing the importance of cell type in the regulation of D1R.
3.3. GRK4 isoforms and renal dopamine receptors
GRK4 is constitutively active. This may be due to its ability to bind
to inactive GαS and Gβ subunits [125]. Unlike the other GRKs, GRK4
has several splice variants. Four GRK4 (GRK4α, β, γ, and δ) splice
variants have been reported in humans, ﬁve in rats, and one in mice
[117,119,121,122,126–128]. Only the GRKα in humans, GRK4A in
rats, and the only GRK4 reported in mice are closely homologous
(approximately 70%) [119,126,127].
The GRK4 isoform that desensitizes D1R and D3R is cell-speciﬁc;
GRK4γ in CHO and human renal proximal tubule cells [112,129].
GRK4α also desensitizes D1R in HEK-293 cells [113,114], and D3R in
human renal proximal tubule cells [129]. There is also GRK4 isoform-
speciﬁc regulation of other GPCRs. GRK4α desensitizes the metabo-
tropic glutamate receptor [130], G protein-coupled calcium-sensing
receptor [131], GABAB [132,133], luteinizing hormone/human chori-
onic gonadotropin receptor [119,134], FSH receptor [135], andmutant
(Y326A) β2 adrenergic receptor [136].
GRK4α does not desensitize the angiotensin type 1 receptor
(AT1R) [137], formyl peptide receptor [138], mGlu4 metabotropic
glutamate receptor [139], mGlu5 metabotropic glutamate receptor
[140], parathyroid hormone receptor [112,141], wild-type β2 adren-
ergic receptor [137,142], and m1, m2, m3, m4, and m5 muscarinic
receptors [143]. GRK4α is also not linked to Gαq [144]. GRK4β
desensitizes the luteinizing hormone/human chorionic gonadotropin
receptor [139], and possibly the V2 vasopressin receptor [145]. GRK4δ
in the presence of GRK5 and GRK6, desensitizes the m2 muscarinic
receptor [143] and luteinizing hormone/human chorionic gonado-
tropin receptor [119], but sensitizes them3muscarinic receptor [143].
GRK4δ does not desensitize D1R (unpublished data). As mentioned
earlier, GRK4γ, especially its gene variants, desensitizes the D1R [112],
and D3R [129], and only at high concentrations does GRK4γminimally
desensitize the luteinizing hormone/human chorionic gonadotropin
receptor [119]. GRK4γwild-type does not desensitize the parathyroid
hormone receptor [122], and AT1R but GRK4 142V and GRK4 486V
may actually increase, directly or indirectly, AT1R expression and
function [146,147]. GRK4 142V increases AT1R expression in mice onnormal salt diet [146], while GRK4 486V increases AT1R expression in
mice on high salt diet [147].
3.4. GRK regulation of dopamine receptors other than D1R (Table 1)
The D2R is regulated by GRK2, GRK3, GRK5, and GRK6 [148,149],
with D2SR affected to a greater extent than D2LR [73]. However, GRK2
or GRK3, but not GRK5 or GRK6, is involved in the desensitization of
the calcium signal mediated by D1R/D2R interaction [150]. The D3R is
regulated by GRK2, GRK3 [151], and GRK4 (GRK4γNGRK4α) [129]
The GRK regulating D4R is not clear but does not seem to involve
either GRK2 or GRK3 [73]. The GRK regulating D5R is also not clear but
does not seem to involve GRK4 [47]. These studies show that the GRK
regulation of dopamine receptor subtypes is GRK isoform-speciﬁc.
3.5. GRK and sodium transporters
GRK2 decreases the degradation of ENaC [152,153]. GRK2 and
GRK3 phosphorylate and may aid in the internalization of Na+K+
ATPase [154]. It is unclear how this effect of GRK2 on D1R
desensitization and decreased internalization of Na+K+ ATPase is
modulated [17–19,23,27,28,37,50,86–91]. NKCC1 colocalizes with
GRK3 in rodent olfactory epithelia, but its regulation by GRK3 has
not been demonstrated [155].
4. GRK4 and essential hypertension
Hypertension is themost expensive disease in the USA. It affects 73
million Americans, causes 50% of heart diseases and 75% of strokes,
and costs in excess of $69 billion in 2008. Hypertension affects a third
of middle-aged adults, but the prevalence is higher (65%) in
individuals above 60 years of age [156,157]. About 30% to 50% of
essential hypertension is thought to be heritable, but the genetic
causes of essential hypertension have been difﬁcult to identify [158].
More than one gene is undoubtedly involved, because Mendelian
dominant and recessive traits are not readily discernible in hyper-
tensive subjects, except in those with monogenic forms of hyperten-
sion. Indeed, recent genome-wide association studies (GWAS) have
been able to identify only 2% of genetic factors believed to inﬂuence
blood pressure [159–164]. However, the GWAS were not designed to
identify predisposing genes engaged in a complex network of gene–
gene and gene/environment interactions [165], e.g., the genes (or
factors) underlying salt sensitivity, a dietary sodium-induced increase
in blood pressure that may or may not be in the hypertensive range.
Several criteria have been suggested to link gene(s) to complex
disorders such as salt sensitivity and hypertension, but the deﬁnitive
evidence is provided by swapping one phenotype for another (i.e.,
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causal of hypertension. Their gene variants, including those identiﬁed
in the GWAS, however, have not been shown to produce hypertension
in mice. Furthermore, gene overexpression and deletion studies
performed in mice must take into account the salt sensitivity of the
strain. C57BL/6 mice from Jackson Laboratories have an impaired
ability to excrete a NaCl load which results in an increase in blood
pressure when their salt intake is increased; others are salt-resistant
(e.g., SJL mice) [167]. We have reported recently that the renal D1-like
receptor function is impaired in salt-sensitive C57BL/6 Jackson mice.
Renal GRK4 expression is increased in salt-loaded C57BL/6 Jackson
mice [167]. Deletion of Grk4 in C57BL/6 mice prevents the
development of salt-sensitive hypertension [168]. Renal D1-like
receptor function is also impaired in the spontaneously hypertensive
rat (SHR), a strain with increased expression of GRK4E. Renal cortical
silencing of GRK4 attenuates the increase in blood pressure with age
in the SHR but not in normotensive Wistar–Kyoto rats whose blood
pressures minimally increase with age [121].
The GRK4 locus on human chromosome 4p16.3 is linked to the
increase in blood pressure from childhood to adulthood [169] and to
hypertension in adults [170]. Interestingly, adolescents with GRK4
65L/142V/A486 haplotype have a greater increase in blood pressure
with age than those with the wild-type GRK4 haplotype [171]. We
have reported [172–174] with subsequent conﬁrmation by others
[175,176] that GRK4 gene variants (65L, 142V, and 486V) are
associated with essential hypertension in several ethnic groups:
Caucasians, Chinese, Ghanaians, and Japanese. In salt-sensitive
hypertensive Japanese the presence of three GRK4 variants impaired
the natriuretic effect of a dopaminergic drug and predicted salt-
sensitive hypertension correctly in 94% of cases [174]. In Ghanaians,
multilocus genotype combinations of angiotensin-converting enzyme
insertion/deletion, and GRK4 65L had an estimated predictive
accuracy for hypertension of 70% [173], conﬁrming an earlier study
[177]. Ameta-analysis revealed a signiﬁcant association of GRK4 486V
with hypertension, with an odds ratio of 1.5 (95% CI: 1.2 to 1.9) [117].
One study however, did not ﬁnd an association of GRK4 486Vwith the
top ﬁfth percentile of diastolic blood pressure of subjects with white
European ancestry [178]. However, the authors did not test the
association of GRK4 gene variants with hypertension [178]. Another
study did not ﬁnd an association between GRK4 142V and
hypertension but did ﬁnd an association between variants of the
promoter region of D1R and hypertension [179]. The discordance
between this report in European Caucasians [179] and other reports
involving other populations may be a result of the inﬂuence of genetic
background in the phenotypic expression of a quantitative trait
essential hypertension. Interestingly, low-renin hypertension is less
frequent in the Caucasian (15–20%) [180] than in other populations
(40–60% in Japanese) [181]. In our Japanese study, the single best
genetic model for low-renin hypertension included only GRK4 A142V,
by itself, or GRK4 A142V and CYP11B2, with an estimated predictive
accuracy of 78% [174]. Ethnicity may also explain some of the
discordances. GRK4 65L and GRK4 142V are less frequent while GRK4
486V is more frequent in Asians than in African-Americans. GRK4
486V is also more frequent in Hispanic and non-Hispanic whites than
in African-Americans [182]. Recent GWAS did not identify GRK4 as
associated with hypertension [158–164]. This is probably because salt
sensitivity and gene–gene interaction were not taken into account.
Previous studies have shown that it was critical to assess the
association of GRK4 with hypertension, in conjunction with other
GRK4 SNPs [174] and genes, e.g., ACE with GRK4 65L [173,177],
ADRB2, TH, and GRK4 486V [176]. GRK4 A142V and GRK4 A486V are,
moreover, not included in the Affymetrix or Illumina platforms,
respectively.
Early in the process of D1R [20,86,183,184] and D3R stimulation
[129], D1R and D3R increase their respective activities, in part, by the
recruitment of intracellular D1R and D3R to the plasma membrane.This recruitment of D1R and D3R to the plasmamembrane requires the
presence of GRK4γ wild-type [129,184]. However, as indicated above
[117], sustained D1R and D3R stimulation results in desensitization
caused by their phosphorylation and internalization. Resensitization
occurs by receptor dephosphorylation, caused by protein phosphatase
2A in D1R [183], and recycling to the plasma membrane. Sorting
nexins also help in the recycling of GPCRs to the plasma membrane.
The GRK4γ wild-type (but not GRK4α wild-type) desensitizes the
AT1R and decreases AT1R expression in the kidney [146,147].
Therefore, GRK4 wild-type is necessary for D1R and D3R [129,184]
to exert their renal autocrine/paracrine natriuretic function, in part by
inhibiting the antinatriuretic effect of AT1R [146,147]. However, GRK4
gene variants constitutively modify, phosphorylate, and internalize
D1R [112] and presumably the D3R also, preventing their recycling to
the plasma membrane. GRK4 gene variants also increase AT1R
expression in mice. This involves GRK4γ 142V on normal salt diet
and by GRK4γ486V on high salt diet [146,147]. While GRK4γ 142V
transgenic mice are hypertensive even on a normal salt diet
[112,146,185], GRK4γ 486V transgenic mice develop hypertension
only when stressed by a high salt diet [147,186]. Depending upon the
genetic background of the mouse, overexpression of human GRK4γ
wild-type converts a salt-sensitive phenotype to a salt-resistant
phenotype, while overexpression of human GRK4γ 486V converts a
salt-resistant phenotype to a salt-sensitive phenotype [146,186].
These phenotype changes, related to differential actions of human
GRK4γ variants and their regulation of D1R and other GPCRs, could be
taken as evidence of the “apparent polygenicity” of hypertension.
GRK4γ 65L transgenic mice are normotensive on a normal salt diet
(unpublished data) but whether or not some form of stress is needed
for the hypertensive phenotype to develop is not known [173,177]. It
is known however, that adolescent African-Americans expressing
GRK4 65L, when exposed tomental stress, respondwith an increase in
blood pressure and a decrease in sodium excretion [187].
4.1. Role of other GRKs in hypertension
GRK activity and GRK2 expression are increased in lymphocytes of
patients with essential hypertension and SHRs [188]. Overexpression
of GRK2 in vascular smooth muscle in mice produces hypertension
and impairs the vasodilatory action of β-adrenoceptors [189]. The
vasoconstrictor response to angiotensin II is also impaired in these
mice, which is at odds with the increased reactivity and sensitivity to
angiotensin II in essential hypertension [190]. Interestingly, GRK2
activates the epithelial sodium channel by phosphorylating the C
terminus of its β subunit, making it insensitive to the inactivating
effects of ubiquitin protein ligases Nedd4 and Nedd2 [191]. Although
GRK2 polymorphisms have not been associated with human essential
hypertension, increased renal expression of GRK2, which is increased
with aging [87], in the insulin/obesity/metabolic syndrome
[52,58,123], and by oxidative stress [32,53,58], impairs D1R function
in rats. More importantly, increased GRK2 expression (but not GRK5)
has been reported in lymphocytes of African-Americans with
hypertension [192]. GRK5 overexpression in vascular smooth muscle
cells in mice also increases blood pressure. The hypertension in male
GRK5 transgenic mice is caused, in part, by decreased β1-adrenergic
receptor activity, whereas the high blood pressure in female mice is
caused, in part, by increased AT1R activity [193]. The increase in GRK5
expression in hypertension may be secondary not primary; angio-
tensin II-induced GRK5 up-regulation in the rat aorta may be due to
hypertension per se [194].
5. GRK4 and pharmacogenomics in essential hypertension
GRK4 polymorphisms may provide predictive pharmacogenetic
insight into therapeutic antihypertensive strategies. In hypertensive
African-Americans, the GRK4 65L/A142 haplotype is predictive of a
Fig. 1. GRK4 and renal dopamine and angiotensin type 1 receptor interaction. During
conditions of moderately increased NaCl intake, the renal D1R is stimulated by
dopamine produced in the kidney. The D1R or D3R, whose coupling to G protein
subunits is regulated by G protein-coupled receptor kinase type 4 (GRK4), inhibits
sodium reabsorption in several nephron segments. This results in an increase in sodium
excretion and maintenance of normal blood pressure. GRK4 wild-type (GRK4 WT) also
negatively regulates AT1R transcription. The decrease in AT1R expression, caused by
GRK4 WT, facilitates the inhibitory effect of D1R on renal sodium transport. In essential
hypertension, constitutively active variants of GRK4 not only uncouple D1R and D3R
from G protein subunits, but also increase AT1R transcription in the kidney. These
effects impair the ability of the kidney to excrete the excess sodium load, resulting in
sodium retention, and ultimately hypertension. Green box= normal coupling of D1R
and D3R to G protein subunits, Red box= uncoupling of D1R and D3R from G protein
subunits. Green arrows = stimulatory, Red arrows = inhibitory.
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studies in hypertensive Japanese suggest that the absolute decrease
in blood pressure in response to angiotensin receptor blockers (ARBs)
is associated with GRK4 142V [196]. (Interestingly, ARBs also
normalize the blood pressure of GRK4γ 142V transgenic mice
[146].) The addition of a diuretic to the non-responders of ARBs
decreased blood pressure in hypertensive Japanese with the GRK4
486V gene variant. These studies suggest that the pharmacogenetics
of GRK4 can be important in guiding the therapy for hypertension.6. Summary
In summary, there is GPCR speciﬁcity of GRK4, especially the
human GRK4γ isoform, in the regulation of human D1R and D3R
(Fig. 1). The human GRK4 locus is linked to hypertension and the
human GRK4 gene variants, either alone or in conjunction with
variants of other genes, are associated with essential hypertension.
The ability of humans with salt-sensitive essential hypertension to
excrete a chronic sodium load is inversely correlated with the number
of human GRK4 allelic variants. Therefore, salt sensitivity may be
imparted by the GRK4 gene variants, and this effect seems to be
dependent on the number of allelic variants present. Human GRK4γ
142V transgenic mice are hypertensive even on a normal sodium
intake while human GRK4γ 486V transgenic mice develop hyperten-
sion only when given a high salt diet. Additional genes contribute to
the predictive value of GRK4 single nucleotide polymorphisms for salt
sensitivity and hypertension, suggesting that epistasis is responsible
for the etiology of this complex polygenic disorder. GRK4 gene
variants may not only be predictive of hypertension phenotypes (e.g.,
salt sensitivity, low plasma renin) but may also predict response to
antihypertensive drugs.Acknowledgements
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